《大行報告》瑞信:內地最新醫保藥品目錄結果符合市場預期
瑞信發表報告指,國家醫療保障局公佈最新醫保藥品目錄談判結果,今年國家醫保目錄共新增74款及取消11款藥物。最新修訂的國家醫保目錄共有2,860款藥品,其中包括西藥1,486款及中藥1,374款。新的目錄將於明年1月1日開始應用。
該行表示,是次新的醫保藥品目錄結果符合市場預期,在74款新增的藥品中,談判成功率及降價水平與歷史水平相當,其中7款新藥是直接進入國家醫保目錄,其餘67款新藥是通過價格談判進入。
瑞信提到,是次有117款藥品合資格作價格談判,當中94款藥品成功完成談判,談判成功率約80%。在完成價格談判的67款新藥中,平均降價幅度爲61.71%。此意味着相對去年的結果,今次有相若數量的成功談判,但降價幅度略高。至於平均降價水平與第四輪的結果一致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.